The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Open accessAbstract
Background Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment.Objective This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain.Design Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase.Results After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 +/- 4.5% compared with 58.7 +/- 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001).Conclusion The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is also evidence that antiobesity medications, including long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, naltrexone/bupropion, phentermine/topiramate, and orlistat, may help maintenance of achieved weight reduction.5,7,8,9,10,11,12”
From Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,453
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Energy and protein requirements*
Pacey, A., & Payne, P. (2019) · Routledge eBooks · doi:10.4324/9780429036279-4 · Cited by 2,545
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Statistical Principles in Experimental Design.
Geisser, S., & Winer, B. J. (1963) · Journal of the American Statistical Association · doi:10.2307/2283359 · Cited by 1,934
(1998) · PubMed · Cited by 1,259
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Beneficial health effects of modest weight loss.
Goldstein, D. J. (1992) · PubMed · Cited by 915
American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease
Eckel, R. H., & Krauss, R. M. (1998) · Circulation · doi:10.1161/01.cir.97.21.2099 · Cited by 807
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 1985, Energy and protein requirement. Report of a joint FAO/WHO/UNU Expert Consultation, World Health Organ Tech Rep Ser, 724
Cited by
Sorted by citations
Items 101–200 of 289
Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance
Shekelle, P., Hardy, M. L., & Morton, S. C. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00147-8 · Cited by 55
Economic Evaluation of Weight Loss Interventions in Overweight and Obese Women
Roux, L., Kuntz, K. M., Donaldson, C., & Goldie, S. J. (2006) · Obesity · doi:10.1038/oby.2006.125 · Cited by 56
Nishioka, T., Hafkamp, A. M., Havinga, R., van Lierop, P. P. E., Velvis, H. J. R., & Verkade, H. J. (2003) · The Journal of Pediatrics · doi:10.1067/s0022-3476(03)00298-1 · Cited by 54
“The mechanism underlying this compensatory phenomenon is presently unclear, but may bear resemblance to the rather limited clinical effects of orlistat during weight reduction regimens.(51;52) Another potential side effect of long-term orlistat treatment, namely deficiency of fat-soluble vitamins,(51) did not occur du…”
ResultKlein, S. (2001) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70182-1 · Cited by 54
Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
Sumithran, P., & Proietto, J. (2014) · Drug Safety · doi:10.1007/s40264-014-0210-7 · Cited by 55
“The potential of orlistat to assist with weight loss maintenance has also been examined in large multicenter studies in which weight loss was induced by a hypocaloric or very-low-energy diet (VLED) and lifestyle modification program, followed by introduction of orlistat or placebo in participants who achieved the targ…”
BackgroundInfluentialA new pancreatic lipase inhibitor from Broussonetia kanzinoki
Ahn, J. H., Liu, Q., Lee, C., Ahn, M., Yoo, H., Hwang, B. Y., & Lee, M. K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.088 · Cited by 52
Curran, M. P., & Scott, L. J. (2004) · Drugs · doi:10.2165/00003495-200464240-00010 · Cited by 52
Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review
Neovius, M., & Narbro, K. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.189 · Cited by 52
Enhancement of pancreatic lipase inhibitory activity of curcumin by radiolytic transformation
Kim, T. H., Kim, J. K., Ito, H., & Jo, C. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.122 · Cited by 50
Jo, Y. H., Kim, S. B., Liu, Q., Do, S., Hwang, B. Y., & Lee, M. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172069 · Cited by 49
Ogawa, A., Kobayashi, T., Sakai, F., Kadooka, Y., & Kawasaki, Y. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0019-0 · Cited by 48
“Pancreatic lipase inhibitors such as orlistat are currently used clinically as pharmaceutical agents [22].”
The use of serotonergic drugs to treat obesity – is there any hope?
Bello, N. T., & Liang, N.-C. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s11859 · Cited by 49
“29 32 The most commonly reported adverse events with orlistat treatment in a large number of subjects (as high as 30% above the control group) were related to mild to moderate gastrointestinal disturbances.”
Lee, I.-C., Bae, J., Kim, T., Kwon, O. J., & Kim, T. H. (2011) · Journal of the Korean Society for Applied Biological Chemistry · doi:10.1007/bf03253166 · Cited by 47
O’Donovan, D., Feinle‐Bisset, C., Wishart, J. M., & Horowitz, M. (2003) · British Journal Of Nutrition · doi:10.1079/bjn2003971 · Cited by 46
“Although the malabsorptive potency of orlistat is maintained with chronic use, the mean weight loss achieved is less than would be predicted by the degree of fat malabsorption (Hill et al. 1999; Kline, 1999), suggesting that some patients taking orlistat may increase their energy intake.”
BackgroundInfluentialLeptin and the treatment of obesity: its current status
Lee, D. W., Leinung, M. C., Rozhavskaya-Arena, M., & Grasso, P. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01424-3 · Cited by 45
A Comparison of Meal Replacements and Medication in Weight Maintenance after Weight Loss
LeCheminant, J. D., JACOBSEN, D. J., Hall, M., & Donnelly, J. E. (2005) · Journal of the American College of Nutrition · doi:10.1080/07315724.2005.10719484 · Cited by 45
“In the present study, approximately 41% of participants reported gastrointestinal problems related to the medication whereas others have reported slightly higher frequency of adverse events [14,27].”
BackgroundObesity and pharmacologic therapy
Thearle, M. S., & Aronne, L. J. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00066-5 · Cited by 45
“In addition, 23% of treated patients maintained 100% of their weight loss versus only 16% of patients in the placebo group [39].”
BackgroundSelf-citationObesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention
Perone, F., Pingitore, A., Conte, E., Hálasz, G., Ambrosetti, M., Peruzzi, M., & Cavarretta, E. (2023) · Healthcare · doi:10.3390/healthcare11060902 · Cited by 46
Obesity: A Review of Pathogenesis and Management Strategies in Adult
Aktar, N., Qureshi, N. K., & Ferdous, H. S. (2017) · Delta Medical College Journal · doi:10.3329/dmcj.v5i1.31436 · Cited by 49
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland
Lacey, L. A., Wolf, A. M., O'Shea, D. B., Erny, S., & Ruof, J. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802947 · Cited by 41
Rosenfalck, A. M., Hendel, H. W., Rasmussen, M. H., Almdal, T., Andersen, T., Hilsted, J., & Madsbad, S. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00161.x · Cited by 41
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Sk, L., & Dc, L. (2002) · doi:10.1002/14651858.cd004094 · Cited by 42
Keating, G. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161140-00011 · Cited by 40
“[11] In large, welldesigned trials involving patients who were overweight or obese but otherwise generally healthy, administration of orlistat 120mg three times daily, compared with placebo, was associated with significantly greater weight loss.[12-22] Improvements in lipid levels were also seen in orlistat recipients.”
Cognitive and Behavioral Approaches in the Treatment of Obesity
Dorsten, B. V., & Lindley, E. M. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.08.003 · Cited by 40
“The call has been sounded to conceptualize obesity as a chronic health condition requiring lifelong treatment.(130) As such, the conceptualization of cognitive-behavioral therapies as a one-time treatment is pass e.”
BackgroundPeirson, L., Fitzpatrick‐Lewis, D., Ciliska, D. K., Ali, M. U., Raina, P. S., & Sherifali, D. (2015) · CMAJ Open · doi:10.9778/cmajo.20140050 · Cited by 38
Vázquez, C., Montagna, C., Alcaraz, F., Balsa, J. A., Zamarrón, I., Arrieta, F., & Botella-Carretero, J. I. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.48 · Cited by 39
“but with modest effects and at the expense of adverse events, as well as non-compliance and rebound weight regain (Hill et al., 1999; Gursoy et al., 2006; Franz et al., 2007).”
BackgroundEffect of Orlistat on Eating Behavior Among Participants in a 3‐year Weight Maintenance Trial
Svendsen, M., Rissanen, A., Richelsen, B., Rössner, S., Hansson, F., & Tonstad, S. (2008) · Obesity · doi:10.1038/oby.2007.82 · Cited by 38
“Orlistat is a pancreatic lipase inhibitor that reduces the intestinal absorption of fat (7,8).”
BackgroundOrlistat: Selective Inhibition of Caloric Absorption Can Affect Long-Term Body Weight
Hauptman, J. B. (2000) · Endocrine · doi:10.1385/endo:13:2:201 · Cited by 38
Self-citationCholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations
Erdmann, J., Lippl, F., Klose, G., & SCHUSDZIARRA, V. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01966.x · Cited by 37
Orlistat in the Treatment of Psychopharmacologically Induced Weight Gain
Anghelescu, I. G., Klawe, C., & Benkert, O. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00029 · Cited by 35
Kimura, H., Ogawa, S., Sugiyama, A., Jisaka, M., Takeuchi, T., & Yokota, K. (2010) · Food Research International · doi:10.1016/j.foodres.2010.10.052 · Cited by 32
Recomendaciones y algoritmo de tratamiento del sobrepeso y la obesidad en personas adultas
Arrizabalaga, J. J., Masmiquel, L., Vidal, J., Calañas-Continente, A., Díaz-Fernández, M. J., García‐Luna, P. P., Monereo, S., Moreiro, J., Moreno, B., Ricart, W., et al. (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)74158-5 · Cited by 32
Proietto, J., Fam, B. C., Ainslie, D. A., & Thorburn, A. W. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1317 · Cited by 32
“Similar results have been presented from studies conducted in the USA [29,30].”
ResultClinical Pharmacology of Sleep
Pandi-Perumal, S. R., & Monti, J. M. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7440-3 · Cited by 31
Sibutramine: current status as an anti-obesity drug and its future perspectives
Sharma, B., & Henderson, D. C. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2161 · Cited by 29
“Orlistat has produced clinically meaningful weight loss sufficient to improve blood pressure, dyslipidaemia and hyperglycaemia compared with placebo in randomized clinical trials lasting 1 – 2 years [6,19,109-116] .”
BackgroundOrlistat and sibutramine beyond weight loss
Mannucci, E., Dicembrini, I., Rotella, F., & Rotella, C. M. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.03.010 · Cited by 29
Obesity and Metabolic Syndrome among Children and Adolescents in Korea
Chu, M. A., & Choe, B. (2010) · Journal of Korean Medical Association · doi:10.5124/jkma.2010.53.2.142 · Cited by 30
Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo
Powell, D. R. (2006) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00220.x · Cited by 28
Spray Dried Smectite Clay Particles as a Novel Treatment against Obesity
Dening, T. J., Joyce, P., Kovalainen, M., Gustafsson, H., & Prestidge, C. A. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2552-9 · Cited by 29
Wadden, T. A., Fujioka, K., Toubro, S., Gantz, I., Erondu, N., Chen, M., Suryawanshi, S., Carofano, W. L., Johnson‐Levonas, A. O., Shapiro, D. R., et al. (2010) · Obesity · doi:10.1038/oby.2010.67 · Cited by 28
Self-citationBray, G. A. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2004.09.009 · Cited by 27
Obesity: an epidemic in need of therapeutics
der Ploeg, L. H. T. V. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00114-9 · Cited by 27
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Does orlistat cause acute kidney injury?
Beyea, M. M., Garg, A. X., & Weir, M. A. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611429985 · Cited by 26
“…Western Ontario, Kidney Clinical Research Unit, Department of Medicine, Division of Nephrology, London, Ontario, Canada Institute for Clinical Evaluative Sciences, Toronto Ontario Canada 54 http://taw.sagepub.com treated with orlistat [Hill et al. 1999; Davidson et al. 1999; Rossner et al. 2000].”
BackgroundTronieri, J. S., Wadden, T. A., Berkowitz, R. I., Chao, A. M., Pearl, R. L., Alamuddin, N., Leonard, S. M., Carvajal, R., Bakizada, Z. M., Pinkasavage, E., et al. (2017) · Obesity · doi:10.1002/oby.22081 · Cited by 25
“ing an initial diet-induced weight loss of 5% (8-10).”
BackgroundMedications for Obesity: Mechanisms and Applications
Bray, G. A. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.05.014 · Cited by 25
Safety profile of orlistat: results of a prescription-event monitoring study
Acharya, N. V., Wilton, L., & Shakir, S. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803323 · Cited by 25
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes
Nelson, R. H., & Miles, J. M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.14.2483 · Cited by 25
“It is noteworthy that orlistat is also effective in preventing weight regain when given to individuals who have already lost weight with lifestyle modification [17].”
BackgroundFurlow, E. A., & Anderson, J. W. (2009) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2009.05.003 · Cited by 25
Self-citationLifestyle Treatments in Randomized Clinical Trials of Pharmacotherapies for Obesity
Poston, W. S. C., Haddock, C. K., Dill, P. L., Thayer, B., & Foreyt, J. P. (2001) · Obesity Research · doi:10.1038/oby.2001.72 · Cited by 25
Orlistat in hypertensive overweight/obese patients
Bloch, K. V., Salles, G. F., Muxfeldt, E. S., & Nogueira, A. D. R. (2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00026 · Cited by 24
A randomized clinical trial of a weight loss maintenance intervention in a primary care population
Tsai, A. G., Felton, S., Wadden, T. A., Hosokawa, P. W., & Hill, J. O. (2015) · Obesity · doi:10.1002/oby.21224 · Cited by 24
“6-month diet run-in period, when most participants achieved their maximum weight loss (12,25,26).”
BackgroundSelf-citationPharmacotherapy for obesity in individuals with type 2 diabetes
Chukir, T., Shukla, A. P., Saunders, K. H., & Aronne, L. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428558 · Cited by 22
“, individuals who received orlistat after they lost 8% of their initial weight by diet alone regained only 33% of lost weight in the first year after treatment compared to 59% in the placebo group [10].”
BackgroundSelf-citationHensrud, D. D. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70231-5 · Cited by 22
Preventing Weight Regain After Weight Loss
Perri, M. G., Foreyt, J. P., & Anton, S. A. (2008) · CRC Press eBooks · doi:10.3109/9781420051452-16 · Cited by 21
Rinde, M., Kupferschmidt, N., Iqbal, M. N., Robert‐Nicoud, G., Johnston, E. V., Lindgren, M., & Bengtsson, T. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0262 · Cited by 20
Cruz‐Hernandez, C., de Oliveira, M. C., Pescia, G., Moulin, J., Masserey‐Elmelegy, I., Dionisi, F., & Destaillats, F. (2010) · Nutrition Research · doi:10.1016/j.nutres.2009.12.001 · Cited by 20
“In the present study, 400 mg and 200 mg of orlistat/kg of diet added to the diet induced a reduction of the dietary lipid absorption in rats by inhibiting gastric and pancreatic lipase activities [4,29,39].”
BackgroundFeigenbaum, A., Pasternak, S., Zusk, E., Sarid, M., & Vinker, S. (2005) · BMC Family Practice · doi:10.1186/1471-2296-6-5 · Cited by 19
“Intense treatment, combining frequent counseling by the family physician and a dietitian with medications (group A), resulted in the best weight reduction and lipid profile improvement in the short period of this study, as was reported earlier in special weight reduction clinics [25-27]”
Katimbwa, D. A., Oh, J., Jang, C. H., & Lim, J. (2022) · Applied Biological Chemistry · doi:10.1186/s13765-022-00712-y · Cited by 19
The war against obesity: attacking a new front
Klein, S. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1061 · Cited by 19
Wang, J., Hudson, R., & Sintim, H. O. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.62 · Cited by 19
Osei-Assibey, G., Adi, Y., Kyrou, I., Kumar, S., & Matyka, K. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01346.x · Cited by 18
“Hill [46] White Caucasians (n = 317) and ethnic minorities (Blacks, non-White Hispanics and Asians) (n = 46) 46.”
BackgroundInfluentialImpact of carbohydrate and fat intake on weight‐reducing efficacy of orlistat
Ullrich, A., Erdmann, J., Margraf, J., & SCHUSDZIARRA, V. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01530.x · Cited by 18
Guía de Práctica Clínica para el Manejo del Sobrepeso y la Obesidad en Personas Adultas
Arrizabalaga, J., Calañas-Continente, A., Vidal, J., Masmiquel, L., Díaz-Fernández, M. L., García-Luna, P., Monereo, S., González, J. A. M., Moreno, B., Ricart, W., et al. (2003) · Endocrinología y Nutrición · Cited by 17
The effect of orlistat on weight reduction in obese and overweight Korean patients
Ahn, S. M., Kim, H., Ji, E., Han, N., & Oh, J. M. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0201-8 · Cited by 14
Bray, G. A., & Ryan, D. H. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.013 · Cited by 18
Effect of protamine in obesity induced by high-fat diets in rats
Duarte-Vázquez, M. A., García‐Padilla, S., Olvera-Ochoa, L., González-Romero, K. E., Acosta-Íñiguez, J., la Cruz‐Cordero, R. D., & Rosado, J. L. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.78 · Cited by 16
An update on the pharmacological treatment of obesity
Schnee, D. M., Zaiken, K., & McCloskey, W. W. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115496 · Cited by 16
Scheen, A. J. (2002) · PubMed · Cited by 16
Regulation of body mass and management of childhood overweight
Daniels, S. R. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20353 · Cited by 15
“There is some concern that there may be diminished absorption of fat-soluble vitaminswith use of Orlistat [26].”
BackgroundTronieri, J. S., Alfaris, N., Chao, A. M., Pearl, R. L., Alamuddin, N., Bakizada, Z. M., Berkowitz, R. I., & Wadden, T. A. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.06.004 · Cited by 14
Seagle, H. M., Wyatt, H. R., & Hill, J. O. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391884-0.00024-x · Cited by 17
Self-citationTackling obesity: new therapeutic agents for assisted weight loss
McFarlane, S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s6552 · Cited by 13
“A multicenter double-blind, placebo-controlled study demonstrated the superiority of orlistat at the dose of 120 mg 3 times a day, when compared to placebo, in preventing weight regain in 729 subjects who succeeded to lose 8% of their initial body weight during a 6-months lead-in of a hypocaloric diet.(42) At 1 year,…”
Cocco, G., Pandolfi, S., & Rousson, V. (2005) · Heart Drug · doi:10.1159/000083662 · Cited by 14
Wolf, C. (2002) · Western Journal of Medicine · doi:10.1136/ewjm.176.1.23 · Cited by 14
Petersen, J., Merrild, C., Lund, J., Holm, S., & Clemmensen, C. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102027 · Cited by 13
Tronieri, J. S., Ghanbari, E., Chevinsky, J., LaFata, E. M., Minnick, A. M., Rajpal, S., Wang, S. Y., Burcaw, K., Berkowitz, R. I., & Wadden, T. A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03556-3 · Cited by 12
Pnlip encoding pancreatic lipase is possible candidate for obesity QTL in the OLETF rat.
Muramatsu, Y., Yamada, T., Taniguchi, Y., Ogino, T., Kose, H., Matsumoto, K., & Sasaki, Y. (2005) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2005.04.040 · Cited by 10
Svendsen, M., Helgeland, M., & Tonstad, S. (2009) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2008.00920.x · Cited by 12
Lignan Derivatives from Fraxinus rhynchophylla and Inhibitory Activity on Pancreatic Lipase
Ahn, J. H., Shin, E., Liu, Q., 김선범, Choi, K. M., Yoo, H., Hwang, B. Y., & Lee, M. K. (2012) · Natural Product Sciences · Cited by 12
Anti-Obesity Drugs: are They Worth It?
Huntington, M. K., & Shewmake, R. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.5 · Cited by 11
Svendsen, M., & Tonstad, S. (2011) · Nutrition Journal · doi:10.1186/1475-2891-10-21 · Cited by 11
“However, randomized clinical trials have shown that the intake of fat in subjects taking orlistat or placebo does not differ substantially [9,10].”
BackgroundInhibitory Activity of Benzophenones from Anemarrhena asphodeloides on Pancreatic Lipase
Jo, Y. H., Kim, S. B., Ahn, J. H., Liu, Q., Hwang, B. Y., & Lee, M. K. (2013) · Natural Product Communications · doi:10.1177/1934578x1300800419 · Cited by 11
“Orlistat, a specific pancreatic lipase inhibitor, has been clinically used for the prevention of obesity [5,6].”
BackgroundDiet and pharmacologic therapy of obesity to modify atherosclerosis
Jones, P. H. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0065-5 · Cited by 10
Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors
Filippatos, T. D., Derdemezis, C. S., & Elisaf, M. (2009) · Clinical Lipidology · doi:10.2217/clp.09.25 · Cited by 11
Lo último en diagnóstico y tratamiento de la obesidad: ¿Hay lugar aún para la terapia conservadora?
Cuevas, A. M., & María Soledad Reyes, S. (2005) · Revista médica de Chile · doi:10.4067/s0034-98872005000600015 · Cited by 10
An update on pharmacotherapeutic strategies for obesity
Tchang, B. G., Tarazi, M. S., Aras, M., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1888927 · Cited by 11
Obesity pharmacology: past, present, and future
Kushner, R. F., & Manzano, H. (2002) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200203000-00011 · Cited by 10
Effects of protamine hydrochloride from chum salmon milt on lipid metabolism in rats
Takahashi, Y., Konishi, T., Enari, H., Lee, H.-S., Lee, W. K., Lee, Y., Park, H. K., & Yamamoto, S. (2011) · Fisheries Science · doi:10.1007/s12562-011-0399-7 · Cited by 9
“In fact, the strong lipase inhibitory agent orlistat has been used for therapy for obesity [16].”
BackgroundArabiyat, S., Al-Rabi'ee, A., Zalloum, H. M., Hudaib, M., Mohammad, M., & Bustanji, Y. K. (2016) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v15i4.8 · Cited by 9
“The success of tetrahydrolipstatin (orlistat) which is a specific pancreatic lipase inhibitor has prompted research to identify new pancreatic lipase inhibitors derived from natural sources [7-9].”
BackgroundPharmacological Treatment of the Overweight Patient
(2007) · Humana Press eBooks · doi:10.1007/978-1-59745-431-5_9 · Cited by 9
Linne, Y. M., & Rössner, S. (2004) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.01.008 · Cited by 9
Obesity treatment: factors involved in weight-loss maintenance and regain
Khaodhiar, L., & Blackburn, G. L. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200210000-00002 · Cited by 9
Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis
Benedictus, B., Pratama, V. K. P., Purnomo, C. W., Tan, K., & Febrinasari, R. P. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.12.013 · Cited by 6
Lean, M., & Campbell, P. T. (2004) · Journal of Drug Evaluation · doi:10.3109/14791130500121412 · Cited by 8
Is blockade of pancreatic lipase the answer?
Halsted, C. H. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1059 · Cited by 8
Graham, M. R., Landgraf, C. G., & Lindsey, C. C. (2003) · Journal of Pharmacy Technology · doi:10.1177/875512250301900601 · Cited by 7
Kolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025) · Cureus · doi:10.7759/cureus.94926 · Cited by 7
Managing obesity like any other chronic condition
Agrawal, M., Worzniak, M., & Diamond, L. M. (2000) · Postgraduate Medicine · doi:10.3810/pgm.2000.07.1158 · Cited by 7
“Therefore, recent studies have focused on long-term weight maintenance with drug therapy.(4)·(8) Candidates for use of weight loss drugs are patients who have failed to lose weight with diet and exercise therapy, have a body mass index greater than 2 7 to 30, or have risk factors or medical conditions caused by obesit…”
Background
Metadata
- Authors
- Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J.
- Affiliations
- Scripps Health (US)
- Corresponding author
- Aronne, Louis J
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 1999-06
- Volume
- 69
- Issue
- 6
- Pages
- 1108-1116
- ISSN
- 0002-9165 (ISSN-L)
- OpenAlex
- W2166266400
- Cited by
- 287
- References
- 26
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 6 · 2012: 10
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- American Journal of Clinical Nutrition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- orlistat, lipase inhibitors, weight maintenance, weight regain, obesity, hypocaloric diet, long-term weight loss, LDL cholesterol, total cholesterol
- MeSH terms
- Orlistat, Adult, Behavior Therapy, Cardiovascular Diseases, Dietary Fats, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Lactones, Lipase, Cholesterol, HDL, Male, Obesity, Risk Factors, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
